ASX - By Stock
|
NEU |
Re:
Ann: Neuren completes Phelan-McDermid syndrome Phase 2 trial
|
|
70FAB
|
51 |
29K |
13 |
14/11/23 |
14/11/23 |
ASX - By Stock
|
51
|
29K
|
13
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren completes Phelan-McDermid syndrome Phase 2 trial
|
|
70FAB
|
51 |
29K |
1 |
14/11/23 |
14/11/23 |
ASX - By Stock
|
51
|
29K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren completes Phelan-McDermid syndrome Phase 2 trial
|
|
70FAB
|
51 |
29K |
15 |
14/11/23 |
14/11/23 |
ASX - By Stock
|
51
|
29K
|
15
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Rett Syndrome NDA accepted for Priority Review by FDA
|
|
70FAB
|
163 |
82K |
12 |
27/02/23 |
27/02/23 |
ASX - By Stock
|
163
|
82K
|
12
|
|